Research Analysts Set Expectations for BioMarin Pharmaceutical Inc.’s FY2025 Earnings (NASDAQ:BMRN)

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Research analysts at Leerink Partnrs dropped their FY2025 EPS estimates for BioMarin Pharmaceutical in a research note issued to investors on Tuesday, April 16th. Leerink Partnrs analyst J. Schwartz now anticipates that the biotechnology company will post earnings of $1.98 per share for the year, down from their prior forecast of $2.16. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $1.85 per share. Leerink Partnrs also issued estimates for BioMarin Pharmaceutical’s FY2026 earnings at $2.37 EPS.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings results on Thursday, February 22nd. The biotechnology company reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. BioMarin Pharmaceutical had a net margin of 6.93% and a return on equity of 5.01%. The company had revenue of $646.21 million during the quarter, compared to analyst estimates of $639.53 million. During the same period in the prior year, the business posted $0.11 EPS. The business’s revenue for the quarter was up 20.2% compared to the same quarter last year.

Other research analysts also recently issued reports about the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $100.00 price objective on shares of BioMarin Pharmaceutical in a research report on Friday, February 23rd. Stifel Nicolaus reiterated a “buy” rating and set a $101.00 price target on shares of BioMarin Pharmaceutical in a report on Thursday, December 21st. Robert W. Baird cut their price target on BioMarin Pharmaceutical from $127.00 to $104.00 and set an “outperform” rating for the company in a report on Tuesday, January 30th. Piper Sandler decreased their price objective on BioMarin Pharmaceutical from $115.00 to $107.00 and set an “overweight” rating on the stock in a report on Friday, February 23rd. Finally, Canaccord Genuity Group restated a “hold” rating and set a $91.00 price objective on shares of BioMarin Pharmaceutical in a research report on Thursday, February 29th. Seven analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, BioMarin Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus target price of $107.61.

BioMarin Pharmaceutical Price Performance

NASDAQ BMRN opened at $90.47 on Thursday. The company has a current ratio of 2.51, a quick ratio of 1.57 and a debt-to-equity ratio of 0.12. The company has a market cap of $17.07 billion, a PE ratio of 102.81, a PEG ratio of 1.69 and a beta of 0.31. BioMarin Pharmaceutical has a 1 year low of $76.02 and a 1 year high of $100.31. The stock’s 50-day moving average price is $87.57 and its two-hundred day moving average price is $89.11.

Insider Transactions at BioMarin Pharmaceutical

In related news, insider Henry J. Fuchs sold 35,341 shares of the firm’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $85.18, for a total transaction of $3,010,346.38. Following the completion of the sale, the insider now directly owns 212,117 shares of the company’s stock, valued at approximately $18,068,126.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider Henry J. Fuchs sold 35,341 shares of the stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $85.18, for a total transaction of $3,010,346.38. Following the sale, the insider now owns 212,117 shares in the company, valued at $18,068,126.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jean Jacques Bienaime sold 15,000 shares of the firm’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $88.28, for a total value of $1,324,200.00. Following the completion of the sale, the director now owns 419,602 shares of the company’s stock, valued at $37,042,464.56. The disclosure for this sale can be found here. Insiders have sold 103,229 shares of company stock valued at $9,062,967 in the last three months. 1.84% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On BioMarin Pharmaceutical

Large investors have recently modified their holdings of the stock. Capital Research Global Investors raised its position in BioMarin Pharmaceutical by 79.0% in the 4th quarter. Capital Research Global Investors now owns 10,774,641 shares of the biotechnology company’s stock worth $1,038,907,000 after purchasing an additional 4,756,671 shares during the last quarter. Norges Bank acquired a new stake in shares of BioMarin Pharmaceutical in the 4th quarter valued at $324,098,000. Barclays PLC raised its position in shares of BioMarin Pharmaceutical by 31.6% during the third quarter. Barclays PLC now owns 5,573,157 shares of the biotechnology company’s stock worth $493,111,000 after acquiring an additional 1,336,886 shares during the last quarter. Toronto Dominion Bank lifted its stake in shares of BioMarin Pharmaceutical by 1,832.5% during the third quarter. Toronto Dominion Bank now owns 907,754 shares of the biotechnology company’s stock valued at $80,318,000 after acquiring an additional 860,782 shares during the period. Finally, Viking Global Investors LP lifted its stake in shares of BioMarin Pharmaceutical by 16.0% during the fourth quarter. Viking Global Investors LP now owns 4,889,454 shares of the biotechnology company’s stock valued at $471,441,000 after acquiring an additional 673,998 shares during the period. 98.71% of the stock is currently owned by institutional investors and hedge funds.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.